Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
43results about How to "Reduce drug dose" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Combined Active and Passive Targeting of Biologically Active Agents
InactiveUS20070287680A1Good curative effectLow in DOPolypeptide with localisation/targeting motifOrganic active ingredientsActive agentEfficacy
Disclosed is a conjugate comprising a biologically active agent (drug) linked to a subcellular targeting moiety that targets a drug specifically to the nucleus. Targeting is achieved by attaching a steroid hormone (or an analog) to the drug. The steroid hormone attached to the drug binds its corresponding receptor, the formation of the receptor-ligand complex results in the internalization of the complex into the nucleus, thus resulting in nuclear translocation of the drug. Also disclosed is a conjugate (comprising the complex of the drug and the steroid hormone) bound to a polymer by spacers allowing for concurrent passive targeting to the tumor cell (afforded by attachment to the polymer by the EPR effect) and nuclear targeting of the conjugate (due to the presence of the steroid). Using a suitable degradable spacer allows for the release of free drug in the tumor and enhances nuclear targeting efficacy. The polymer can be further linked to a cellular targeting molecule, where the targeting molecule directs the polymer to specific cells. One may thus be able to effectively target drugs to the nucleus of tumor cells. With little or modifications, several therapeutic agents can be targeted using the invention.
Owner:UNIV OF UTAH RES FOUND
In vivo inhibition of hepatitis B virus
InactiveUS20060063731A1Reduce the amount requiredReduce drug doseBiocideSpecial deliveryNucleotideMammal
A process is provided to deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similarity to of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of the polynucleotide-based gene expression inhibitor can enhance the efficacy of co-delivered small molecule drugs.
Owner:ROCHE MADISON
Fine Particle-Containing Composition and Manufacturing Method Therefor
The present invention provides a composition containing fine particles of a hardly-soluble drug which is stable and is not affected by storage environment conditions, as well as a manufacturing method therefor. The present invention provides a fine particle-containing composition containing fine particles of the hardly-soluble drug, a surfactant and a cyclic oligosaccharide, wherein an average particle size of the fine particles is at least 50 nm but not more than 1000 nm. The present invention also provides a method for manufacturing a fine particle-containing composition, comprising (I) a mixing step in which the hardly-soluble drug, the surfactant and a poor solvent are mixed to obtain a liquid mixture, (II) a pulverization step in which the liquid mixture is pulverized with a wet disperser to obtain a dispersion of fine particles, (III) an addition step in which the cyclic oligosaccharide is added to the dispersion of fine particles, and (IV) a drying step in which the dispersion of fine particles containing the cyclic oligosaccharide is dried.
Owner:EISIA R&D MANAGEMENT CO LTD
Network biology approach for identifying targets for combination therapies
InactiveUS20110119259A1Good curative effectEliminate side effectsDigital data processing detailsSystems biologySide effectDrug compound
Described herein is a network biology approach useful for the identification of multiple therapeutic targets, which can be targeted simultaneously using an agent (or a plurality of agents) to modulate cellular phenotypes, or in combination with pharmaceutical compounds to improve drug sensitivity and / or reduce drug doses to maintain efficacy while minimizing side effects. The preferred approach disclosed herein relies on first identifying the mediators of a condition of interest, and second, selecting gene combinations that are in competing / parallel pathways as targets for combination therapy.
Owner:TRUSTEES OF BOSTON UNIV
Method for administrating preparations containing peramivir and/or derivatives thereof
InactiveCN103446051AReduce drug doseLittle side effectsPowder deliveryOrganic active ingredientsOral medicationIntravenous use
The invention relates to a method for administrating preparations containing peramivir and / or derivatives thereof. Administration is carried out through inhalation. The method can be used for treating cold caused by influenza viruses. By adopting the administration method provided by the invention, not only can dependence on the single variety of drugs such as oseltamivir and zanamivir be reduced and new drug resistant virus strains generated by using the single variety in quantity be avoided but also the method which is favorable for greatly improving the bioavailability compared with oral administration or intravenous drip is provided for peramivir and / or derivatives thereof; more importantly, the method which has the advantages of small drug dose, less side effects and high effect taking speed is provided.
Owner:陈永奇 +2
Niclosamide formulations for treating disease
ActiveUS11045434B1Improve solution stabilityIncrease concentrationPowder deliveryOrganic active ingredientsDiseaseCyclodextrin
The invention relates to a method of treating a viral infection caused by or associated with SARS-CoV-2 in a subject, the method comprising administering to the subject by inhalation intraorally and / or intranasally a therapeutically effective amount of a formulation comprising niclosamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.
Owner:UNION THERAPEUTICS AS
Therapeutic placebo enhancement of commonly used medications
InactiveUS20050136106A1Less pharmaceuticalReduced effectivenessPill deliveryHeterocyclic compound active ingredientsUse medicationDisease
There is provided a method and associated kit for reducing the normal dosage of a pharmaceutical given to a patient for the treatment of a disorder without substantially reducing its effectiveness. During a first predetermined time period, a substantially full dosage of the pharmaceutical is administered to the patient, preferably with a placebo. During a second predetermined time period, a reduced dosage of the pharmaceutical is administered to the patient, also with a placebo. The second predetermined time period is subsequent to the first predetermined time period. Preferably, the placebo has a distinctive indicia. The placebo, in association with the decreased pharmaceutical, augments the effectiveness of the pharmaceutical by heightening the patient's conditioned response and expectation of effectiveness.
Owner:SANDLER ADRIAN
Peptide marker targeting to nasopharyngeal carcinoma cell and application thereof
ActiveUS7238665B2Good curative effectReduce drug dosePeptide/protein ingredientsImmunoglobulinsChemotherapeutic drugsNasopharyngeal carcinoma
Owner:NAT TAIWAN UNIV
Biocompatible polymeric compositions having microcrystalline and amorphous components and methods for their manufacture
ActiveUS8992949B1Improve securityImprove effectivenessOrganic non-active ingredientsSolution deliveryPolymer alloyBiocompatible polymers
Compositions comprising a polymer-based macroscopically homogeneous polymer alloy comprising a plurality of microcrystalline components dispersed within an amorphous component, which is biocompatible, bioerodable, substantially non-toxic, and excretable, or metabolized when introduced into a mammalian body. In preferred embodiments, malleable molded devices such as implants, films, drug delivery systems and the like, are comprised of the compositions. Methods of making such compositions by controlled cooling of the molten alloy are also described.
Owner:UNICARE BIOMEDICAL
Peptide marker targeting to nasopharyngeal carcinoma cell and application thereof
ActiveUS20050010036A1Good curative effectReduce drug doseHybrid immunoglobulinsPeptide/protein ingredientsChemotherapeutic drugsNasopharyngeal carcinoma
The present invention provides a peptide marker targeting to nasopharyngeal carcinoma (NPC) cells and application thereof. The peptide binds specifically to the cell surface of NPC cells. After conjugated with liposome containing chemotherapeutic drugs, such peptides deliver chemotherapeutic drugs to the tumor cells specifically and destruct tumor cells without damaging normal tissues and organs. Furthermore, such peptide is applied as a detector in the development of NPC diagnosis kit.
Owner:NAT TAIWAN UNIV
Liposome Preparation
InactiveUS20090169610A1Improve targetingReduce drug doseOrganic active ingredientsAntibody ingredientsGnRH AntagonistLiposome
The present invention provides cancer treatment preparations of excellent targetability. The sugar chain-modified liposomes of the present invention, which contain an aromatase inhibitor, anti-androgenic agent, lyase inhibitor, GnRH agonist, GnRH antagonist, anti-angiogenic agent, tyrosine kinase inhibitor, serine-threonine kinase inhibitor, antibody having an anticancer activity, ansamitocin, capecitabine, celmoleukin, docetaxel hydrate, gemcitabine hydrochloride, oxaliplatin, prednisolone, tegafur-uracil mixtures, zinostatin stimalamer or arsenic trioxide may be used as cancer treatment preparations having an excellent targetability.
Owner:SIEMENS AG +1
Celecoxib formulations useful for treating colorectal cancer
InactiveUS20150342893A1Reduce gastrointestinal side effectsEliminate side effectsBiocideOrganic active ingredientsLymphatic SpreadSURFACTANT BLEND
An oral celecoxib formulation, the formulation being a multiple minibead formulation wherein the minibeads comprise a hydrogel-forming polymer matrix in which are distributed celecoxib, a polyoxyethylated non-ionic surfactant and an anionic surfactant, the minibeads when combined with water being capable of releasing self-assembly structures comprising surfactant and celecoxib.The formulation may be used for treating colorectal cancer, e.g. for inhibiting, reducing or delaying the initiation and / or progression of colorectal cancer, or for use in reversing colorectal cancer, reducing the burden of colorectal cancer and / or inducing remission of colorectal cancer, or for inhibiting, reducing or delaying metastasis of a colorectal cancer.
Owner:SIGMOID PHARM LIMITED
Method and system for leading macromolecule substances into living target cells
InactiveUS20050085711A1EfficientlyImprove efficiencyUltrasonic/sonic/infrasonic diagnosticsElectrotherapyPOLYMER SUBSTANCEMedicine
A method and system for leading macromolecule substances into target cells includes an image picking unit, an image merging unit, an injection unit, and an energy conversion module. The image picking unit is used for picking up the three-dimensional (3D) and the 3D blood vessel photographic images of the tissue or organ where the target cells locate. The image merging unit is used for merging the 3D structure images into the 3D blood vessel photographic images, therefore choosing a blood vessel passage fully covering the target cells for transmitting the macromolecule substances. The injection unit is used for injecting liquid and transmitting the macromolecule substances to the target cells. The energy conversion module is used for exerting energy to activate the liquid to perform biological effects, thereby forming non-permanent holes in the cell membranes of the target cells. The macromolecule substances enter into the target cells through the non-permanent holes.
Owner:TIEN DER YANG
Medical use of 7-hydroxy-butylphthalide
ActiveCN106214674AImprove protectionStrong medicinal effectOrganic active ingredientsAntinoxious agentsVascular diseaseButylphthalide
The invention belongs to the technical field of pharmaceutical chemistry and particularly relates to medical use of 7-hydroxy-butylphthalide in preparation of drugs for preventing and / or treating cardiac and cerebral vascular diseases.
Owner:NCPC NEW DRUG RES & DEV
Percutaneously absorbable preparation containing fentanyl and homologue thereof
InactiveUS20140243765A1Improve penetration efficiencyReduce drug doseBiocideAdhesive dressingsAdhesiveFentanyl
Disclosed is a transdermal preparation, comprising sequentially-stacked layers of a backing layer, a barrier layer, a drug adhesive layer and a release layer, wherein the drug adhesive layer contains a drug selected from the group consisting of fentanyl, an analogue thereof and a pharmaceutically-acceptable salt thereof, a skin permeation enhancer of the drug, and a polyacrylate adhesive, which shows a high skin permeation with a low drug dosage, equivalent to one with high drug dosage, by increasing the skin permeation rate of drug.
Owner:SAMYANG BIOPHARMLS CORP
Balloon dilatation catheter for interruption
InactiveCN106137295AIncrease concentrationConvenient treatmentInfusion devicesMedical devicesBalloon dilatation catheterHigh concentration
The invention discloses a blocked balloon dilation catheter. The front end of the balloon dilation catheter is a working area, the rear end of the working area is provided with a first blocking balloon, and the front end of the working area is provided with a second blocking balloon. Balloons, a drug administration micropore is arranged between the two blocking balloons, and the drug administration micropore is close to one of the blocking balloons; a working ball is arranged between the drug administration micropore and the balloon far away from the drug administration micropore A balloon, the effective length of the working balloon is greater than half of the distance between the drug delivery microhole and the balloon away from the drug delivery microhole. The blocked balloon dilation catheter of the present invention arranges a working balloon between the two balloons at the front end of the balloon dilation catheter, and squeezes the closed space between the two balloons into a thin-walled annular columnar shape, reducing At the same time, before removing the blocking, the pressure of the working balloon is released, and the diluent is added to dilute the liquid medicine, so as to avoid the damage of the high-concentration liquid medicine to the organs.
Owner:谷涌泉
Magnetically-controllable nanometric porous drug carrier
The present invention discloses a magnetically-controllable nanometric porous drug carrier, wherein an organic or inorganic matrix is used to carry the drug, and wherein magnetic nanoparticles having magnetosensitivity are used to encapsulate the surface of the matrix and seal the drug inside the matrix. An external magnetic field is used to control the removal rate of the magnetic nanoparticles and control the behavior and rate of drug release.
Owner:NAT CHIAO TUNG UNIV
Phosphatide granule with subsidiary function of reducing blood fat
ActiveCN1739584ABlood lipid preventionImprove lipid metabolismOrganic active ingredientsMetabolism disorderVitamin CAdditive ingredient
The phosphatide granule with subsidiary function of reducing blood fat consists of lecithin 16-60 wt%, tea polyphenol 1.0-2.5 wt%, ginkgo extract with 24 % over total flavone glycoside 0.39-1.5 wt%, vitamin C 1-5 wt%, vitamin E 0.16-1.5 wt%, vitamin B1 0.02-0.2 wt%, vitamin B2 0.02-0.2 wt% and starch 29.1-91.41 wt%. The present invention has several health functions, including emulsifying blood fat, preventing oxidation, accelerating fat metabolism and eliminating fat toxin, and thus can lower blood fat, raise body's immunity and strengthen physique.
Owner:北京东方倍力营养科技有限公司
Device and method for improving retention of a therapy in the bladder
InactiveUS20210100950A1Extended durationMinimal inflammationPowder deliveryInfusion syringesTreatment retentionActive agent
Devices that are placed within fluid filled organs, such as the bladder, which reduce the risk of bacterial infections using a combination of active agents and mechanical disruption of bacteria.
Owner:WATERSHED MEDICAL INC
Niclosamide formulations for treating disease
ActiveUS11324708B1Improve solution stabilityIncrease concentrationPowder deliveryOrganic active ingredientsDiseaseCyclodextrin
The invention relates to a method of treating a viral infection caused by or associated with SARS-CoV-2 in a subject, the method comprising administering to the subject by inhalation intraorally and / or intranasally a therapeutically effective amount of a formulation comprising niclosamide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin.
Owner:UNION THERAPEUTICS AS
Novel macrolide derivatives havaing effect of potentiating antifungal activity
Macrolide derivatives having enhancing effect for activities of azole antifungal agents, acting at low concentration and within a short time against fungal infection and reducing the frequency of appearance of resistant microorganisms. One such substance is a compound represented by the formula [I]: wherein R1 is Ac, R2 and R3 are Ac, and R4 is Me; when R1 is H, R2 and R3 are Ac, and R4 is Me; when R1 is H, R2 and R3 are Ac, and R4 is H, when R1 Bzl, R2 and R3 are Bzl, and R4 is Me; when R1 is Ac, R2 and R3 are Pr, and R4 is Me; when R1 is Ac, R2 and R3 are Hex, and R4 is Me; when R1 is Ac, R2 and R3 are Bzl, and R4 is Me; when R1 is H, R2 and R3 are Pr, and R4 is Me; when R1 is H, R2 and R3 are Hex, and R4 is Me; when R1 is H, R2 and R3 are Bzl, and R4 is Me; when R1 is H, R2 is H, R3 is Bzl, and R4 is Me; when R1 is H, R2 and R3 are Hex, and R4 is H, or when R1 is H, R2 and R3 are Hex, and R4 is Et.
Owner:THE KITASATO INST
External use type traditional Chinese medicine composition, and extract, preparation and application thereof
The invention discloses an external use type traditional Chinese medicine composition, and an extract, preparation and application thereof. The external use type traditional Chinese medicine composition is prepared from, by weight, 3-30 parts of semen cuscutae, 1.5-15 parts of fructus psoraleae, 3-30 parts of folium artemisiae argyi, 0.5-5 parts of cortex cinnamomi and 1-10 parts of rhizoma chuanxiong. The composition can treat both symptoms and root causes through acupoint application and transdermal absorption, stomachache caused by cold in uterus can be treated comprehensively, cold in uterus is relieved fundamentally, and therefore stomachache caused by cold in uterus is improved. The external use type traditional Chinese medicine composition can also be combined with mild moxibustion for indirect moxibustion treatment, so that fast relief and treatment of stomachache can be achieved, using is convenient, gastrointestinal tract side effects of drugs are avoided, and influences on hepatic and renal functions are reduced.
Owner:SHANGHAI RONGXUAN BIOTECH
Compositions and Methods For Delivery Of Polyunsaturated Fatty Acid Derivatives And Analogs
ActiveUS20180280318A1Improve bioavailabilityLong exposure timeHydroxy compound active ingredientsAntipyreticMetaboliteAntioxidant
The present invention provides a system enabling the oral delivery of therapeutics derived from polyunsaturated fatty acids (PUFAs), their metabolites and derivatives, including, eicosanoids, prostaglandins, prostacyclins, leukotrienes, resolvins, endocannabinoids, thromboxanes, epoxyeicosa-trienoic acids (EETs), hydroxyeicostetraenoic acids (HETEs), and CMX-020. The delivery system includes a vehicle comprising a purified docosahexaenoic acid (DHA) in triglyceride or ester form; a purified eicosapentaenoic acid (EPA) in triglyceride or ester form; a combination of DHA, EPA in either triglyceride or ester forms; or a modified DHA, EPA, or omega-3 fatty acid analog; and optionally, an antioxidant, a surfactant, a solubilizer, a stabilizer, a lubricant, or a pH / tonicity adjustment agent.
Owner:CYTOMETIX INC D B A CMXTWENTY
Method and system for leading macromolecule substances into living target cells
InactiveUS7415302B2EfficientlyImprove efficiencyUltrasonic/sonic/infrasonic diagnosticsElectrotherapyCell membraneMacromolecular Substances
Owner:TIEN DER YANG
Preparation method and application method for melatonin dropping pill
InactiveCN105663061AReduce drug doseImprove sleepingOrganic active ingredientsNervous disorderOral medicationHepatic first pass effect
Directed at the current situation of no buccal melatonin preparation in China, the invention discloses preparation of a buccal melatonin dropping pill. The prepared dropping pill weighs 0.01 to 0.09 g (i.e., 10 to 90 mg) and contains 1.0 to 6.0 mg of melatonin. The application method for melatonin dropping pill is to keep one or more melatonin dropping pills in the mouth in 10 to 60 min before sleeping and allow the pills to naturally thaw before sleeping. According to the invention, the first pass effect of oral administration of a melatonin oral liquid or melatonin capsule is prevented, and sleep can be rapidly improved by using a small dosage of the melatonin dropping pill. The properties, dissolving and dispersion limits, stability and other indexes of the melatonin dropping pill prepared in the invention accord with related requirements for dropping pills prescribed in Chinese Pharmacopeia.
Owner:刘佳迪
Method and System for Leading Macromolecule Substances into Living Target Cells
InactiveUS20080247625A1EfficientlyImprove efficiencyGenetic material ingredientsDiagnosticsCell membraneComputer module
Owner:TIEN DER YANG
Inhalable liposomal sustained release composition for use in treating pulmonary diseases
ActiveUS20210145740A1Improve drug bioavailabilityReduce drug doseDispersion deliverySolution deliveryDiseasePolyethylene glycol
Provided is a liposomal sustained-release composition for use in treatment of pulmonary disease. The liposomal sustained release composition comprises a liposome that includes a polyethylene glycol (PEG)-modified lipid and encapsulates a tyrosine kinase inhibitor. Tyrosine kinase inhibitor is stably entrapped in the liposome, and the resulting liposomal drug formulation can be aerosolized or nebulized for administration via inhalation. This aerosolized liposomal drug formulation yields consistent pharmacokinetic and pharmacodynamic profiles while achieving desired efficacy and safety.
Owner:INSPIRMED CORP
Method and system for leading macromolecule substances into living target cells
InactiveUS20090076391A1EfficientlyImprove efficiencyUltrasonic/sonic/infrasonic diagnosticsSurgeryCell membraneMacromolecular Substances
A method and system for leading macromolecule substances into target cells includes an image picking unit, an image merging unit, an injection unit, and an energy conversion module. The image picking unit is used for picking up the three-dimensional (3D) and the 3D blood vessel photographic images of the tissue or organ where the target cells locate. The image merging unit is used for merging the 3D structure images into the 3D blood vessel photographic images, therefore choosing a blood vessel passage fully covering the target cells for transmitting the macromolecule substances. The injection unit is used for injecting liquid and transmitting the macromolecule substances to the target cells. The energy conversion module is used for exerting energy to activate the liquid to perform biological effects, thereby forming non-permanent holes in the cell membranes of the target cells. The macromolecule substances enter into the target cells through the non-permanent holes.
Owner:TIEN DER YANG
Icodextrin-containing formula food for diabetes
The invention belongs to the field of foods, and particularly relates to icodextrin-containing formula food for diabetes. The formula food comprises the following components: protein, fat, carbohydrates, dietary fibers, taurine, L-carnitine, minerals, vitamins, an emulsifier and water. The carbohydrates include icodextrin and other carbohydrates. The icodextrin-containing formula food for the diabetes disclosed by the invention is comprehensive in nutrition and scientific in matching; long-term complications are avoided by controlling metabolism of diabetes patients, clinical highly-related short-term complications are reduced, and drug dosage is reduced, thereby reducing drug-related side effects; and the food is an important nutrition source for hyperglycemia and diabetic traumas causedby the diabetes, glucose intolerance and pressure.
Owner:HUAREN PHARMACEUTICAL CO LTD +3
Application of traditional Chinese medicine Burnet in the preparation of antifungal drug synergists
InactiveCN104857116BReduce drug doseEnhanced inhibitory effectAntimycoticsPlant ingredientsMedicineDrug resistance
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com